7/12/2013

Johnson & Johnson's Janssen Biotech and Pharmacyclics have filed an application with the FDA for approval to market their experimental drug ibrutinib for treatment of mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma using data from two midstage studies. Ibrutinib was granted breakthrough therapy designations for three indications by the FDA.

Full Story:
PharmaTimes (U.K.)

Related Summaries